Long overdue. US has been paying higher prices to drug companies to subsidize Canada and Europe gettimg cheaper prices. Have long negotiated on Medicaid.
- The government estimates that the new prices could produce $6 billion in net savings for Medicare in 2026 alone, based on data from 2023.
- It is a milestone in a controversial process that aims to make costly medications more affordable for older Americans, a policy the pharmaceutical industry has opposed.
- It comes one day before the second anniversary of President Joe Biden’s signature Inflation Reduction Act....,,
Here are the negotiated prices for a 30-day supply of the 10 drugs, along with their list prices based on 2023 prescription fills, according to a Biden administration fact sheet Thursday. Notably, what Medicare and beneficiaries pay for a drug is often much less than the list price, which is the what a wholesaler, distributor or other direct purchaser paid a manufacturer for a medication before any discounts.
- Eliquis, made by Bristol Myers Squibb – $231.00 negotiated price, $521 list price
- Jardiance, made by Boehringer Ingelheim and Eli Lilly – $197.00 negotiated price, $573.00 list price
- Xarelto, made by Johnson & Johnson – $197.00 negotiated price, $517.00 list price
- Januvia, made by Merck – $113.00 negotiated price, $527.00 list price
- Farxiga, made by AstraZeneca – $178.50 negotiated price, $556.00 list price
- Entresto, made by Novartis – $295.00 negotiated price, $628.00 list price
- Enbrel, made by Amgen – $2,355.00 negotiated price, $7,106.00 list price
- Imbruvica, made by AbbVie and J&J – $9,319.00 negotiated price, $14,934.00 list price
- Stelara, made by Janssen – $4,695.00 negotiated price, $13,836.00 list price
- Fiasp and NovoLog, made by Novo Nordisk – $119.00 negotiated price, $495.00 list price